{"id":7679,"date":"2025-11-13T07:30:00","date_gmt":"2025-11-13T07:30:00","guid":{"rendered":"https:\/\/realheart.se\/mfn_news\/scandinavian-real-heart-ab-changes-date-for-extraordinary-general-meeting\/"},"modified":"2025-11-13T07:30:00","modified_gmt":"2025-11-13T07:30:00","slug":"scandinavian-real-heart-ab-changes-date-for-extraordinary-general-meeting","status":"publish","type":"mfn_news","link":"https:\/\/realheart.se\/sv\/mfn_news\/scandinavian-real-heart-ab-changes-date-for-extraordinary-general-meeting\/","title":{"rendered":"Scandinavian Real Heart AB changes date for Extraordinary General Meeting"},"content":{"rendered":"
\n

On October 24, 2025, the Board of Directors of Scandinavian Real Heart AB (publ) convened an Extraordinary General Meeting scheduled to be held on November 24, 2025. However, the notice has not been published in the Swedish Official Gazette, which is a statutory requirement under the Swedish Companies Act.<\/strong><\/p>\n<\/div>\n

\n

Due to this, the Board of Directors has decided to change the date of the Extraordinary General Meeting. A new notice has been sent out on 13 November 2025<\/strong> in accordance with current regulations. The new date for the Extraordinary General Meeting is 16 December 2025<\/strong> at 5:30 p.m. at Best Western Plus Hotel Plaza, Kopparbergsv\u00e4gen 10, 722 13 V\u00e4ster\u00e5s, Sweden. Registration for the meeting will commence at 5:00 p.m.<\/p>\n

We apologize for the inconvenience and are working to ensure that the process complies with all legal requirements.<\/p>\n

The complete notice including appendices is available on our website:
https:\/\/www.realheart.se<\/a><\/p>\n

Matters to be dealt with at the Annual General Meeting remain unchanged.<\/p>\n<\/div>\n

\n

For more information, please contact:<\/strong>
Ina Laura Perkins, CEO
Phone: +46 (0) 70 406 49 21\u00a0
E-mail: inalaura.perkins@realheart.se<\/a>
Certified Adviser: Svensk Kapitalmarknadsgranskning AB, www.skmg.se<\/a><\/p>\n<\/div>\n

\n

About Us<\/strong>
Scandinavian Real Heart AB (publ) is developing the first artificial heart that mimics the shape, function, and blood flow pattern of the human heart. These unique product features provide completely new opportunities to save lives and give patients a good quality of life while waiting for a heart transplant. In the future, artificial hearts may also become an alternative to transplantation for broader groups of patients with severe heart failure. Realheart\u00ae TAH (Total Artificial Heart) is now being evaluated in extensive preclinical trials ahead of a first clinical study in patients. The company's shares are traded on Nasdaq Stockholm First North Growth Market. For more information, visit www.realheart.se<\/a><\/p>\n<\/div>\n

\n

This information is information that Scandinavian Real Heart is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-11-13 08:30 CET.<\/em><\/p>\n<\/div>\n

\n

Attachments<\/strong>
Scandinavian Real Heart AB changes date for Extraordinary General Meeting<\/a><\/p>\n<\/div>\n